Submissions from 2018
Patient-reported outcomes in chronic hepatitis C: The impact of placebo, active treatment, and sustained viral eradication., Z Younossi, M Stepanova, M P. Manns, R Reddy, Stuart C. Gordon, and M Bourliere
Long-term follow up of patients with chronic HCV and F2 or F3 fibrosis after achieving SVR with DAA-based therapy: Results from the Gilead SVR registry., S Zeuzem, M B. Ferret, E Gane, I Jacobson, Stuart C. Gordon, M Sulkowski, B McNabb, F Chen, H Dvory-Sobol, A Osinusi, D Brainard, M Subramanian, A Ramji, K Agarwal, R Reddy, and M Bourliere
Submissions from 2017
Risk factors and outcomes of intracardiac thrombosis during orthotopic liver transplantation., Waleed Al-Darzi, Mazen M. El-Atrache, F Georgie, Omar Sadiq, Sumit Singla, C Fernandez, Robert Pompa, Dragos Galusca, Atsushi Yoshida, and Syed-Mohammed Jafri
Long-term follow up of patients with chronic HCV and no or minimal fibrosis shows low risk for liver-related morbidity and mortality after achieving SVR with DAA-based therapy: Results from the gilead SVR registry., M Bourlière, E J. Gane, I Jacobsen, Stuart C. Gordon, M S. Sulkowski, B L. McNabb, F Chen, H Dvory-Sobol, J McNally, D M. Brainard, M Subramanian, A Ramji, S Zeuzem, K Agarwal, and K R. Reddy
SOF/VEL/VOX for 12 weeks in NS5A-inhibitor experienced HCV-infected patients: Results of the deferred treatment group in the phase 3 POLARIS-1 study., M Bourlière, Stuart C. Gordon, E R. Schiff, T T. Tran, N Ravendhran, C S. Landis, R H. Hyland, J Zhang, H Dvory-Sobol, Luisa M. Stamm, D M. Brainard, J G. McHutchison, L Serfaty, A J. Thompson, T E. Sepe, M P. Curry, K R. Reddy, and M P. Manns
Cost-effectiveness analysis of first-line administration of tenofovir alafenamide (TAF), a novel nucleotide reverse transcrip-tase inhibitor (NRTI), for the management of chronic hepatitis b (CHB) in the united states (us)., Geoffrey Dusheiko, J Lim, I Liou, A Tafazzoli, B Deniz, C Saint-Laurent Thibault, Stuart C. Gordon, and M H. Nguyen
Health outcomes associated with sofosbuvir- based single-tablet regimens for initial and re-treatment of chronic hepatitis c in the US., Stuart C. Gordon, A Ahmed, S Saab, D T. Dieterich, R J. Wong, M Kugelmas, Kimberly A. Brown, and Z M. Younossi
Treatment efficacy and safety of low dose seladelpar, a selective PPAR-δ agonist, in patients with primary biliary cholangitis: Twelve-week interim analysis of an international, randomized, dose ranging, phase 2 study., G M. Hirschfield, C L. Bowlus, S A. Harrison, M R. Galambos, B B. Borg, Stuart C. Gordon, N Gitlin, TI Hassanein, J A. Odin, B Bacon, D E. Bernstein, J M. Vierling, A Steinberg, Y J. Choi, M Varga, R Martin, C McWherter, P Boudes, and D Jones
Health outcomes among surveyed patients infected with hepatitis C in the Chronic Hepatitis Cohort Study (CHeCS)., M G. Hofmeister, J Xing, A C. Moorman, Loralee B. Rupp, Stuart C. Gordon, J A. Boscarino, M A. Schmidt, Y H. Daida, Mei Lu, E H. Teshale, S D. Holmberg, and P R. Spradling
Measures of adherence to HCV therapy in a specialty pharmacy setting and association with NON-SVR., S A. Kaurala, M Veve, J Van Lare, J S. Mansour, M Andrews, Kimberly A. Brown, and Susan L. Davis
Safety and efficacy of treatment with once-daily ledipasvir/sofosbuvir (90/400 mg) for 12 weeks in genotype 1 hcv-infected patients with severe renal impairment., Eric Lawitz, Charles S. Landis, Benedict Maliakkal, M Bonacini, G Ortiz-Lasanta, J Zhang, E Mogalian, S De-Oertel, A O. Osinusi, D M. Brainard, John G. McHutchison, Steven L. Flamm, Stuart C. Gordon, and E J. Gane
C-BREEZE 1: Efficacy and safety of ruzasvir 60 mg plus uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis c virus (HCV) genotype (GT)1, 2, 3, 4, or 6 infection., Eric Lawitz, F Poordad, L Anderson, M Vesay, H Liu, D Fernsler, E Asante-Appiah, G J. Hanna, M Robertson, E Barr, J R. Butterton, K V. Knowdley, T I. Hasanein, A K. Sahota, Stuart C. Gordon, and W W. Yeh
Does Hepatitis C eradication lead to improved glucose metabolism, renal and cardiovascular outcomes in diabetic patients?, Jia Li, Stuart C. Gordon, Loralee B. Rupp, Talan Zhang, Sheri Trudeau, S D. Holmberg, A C. Moorman, P R. Spradling, E H. Teshale, J A. Boscarino, M A. Schmidt, Y Daida, and Mei Lu
Impact of sustained virological response on incidence of type 2 diabetes in hepatitis c patients., Jia Li, Talan Zhang, Stuart C. Gordon, Loralee B. Rupp, Sheri Trudeau, S D. Holmberg, A C. Moorman, P R. Spradling, E H. Teshale, J A. Boscarino, M A. Schmidt, Y H. Daida, and Mei Lu
Epidemiologic trends and treatment survival benefits in a US cohort of patients with primary biliary cholangitis (PBC)., Mei Lu, Yueren Zhou, I Haller, R Romanelli, J J. VanWormer, C V. Rodriguez, H Anderson, J A. Boscarino, M A. Schmidt, Y Daida, A K. Sahota, J Vincent, C L. Bowlus, K D. Lindor, T Zhang, Sheri Trudeau, Jia Li, Loralee B. Rupp, and Stuart C. Gordon
Contemporary outcomes and risk factors of acute graft-versus-host disease after liver transplant., J Markus, A Bukannan, B Kashat, and Reena Salgia
The impact of the donor risk index on tumor free survival in patients undergoing liver transplantation with hepatocellular carcinoma., D Moonka, Shunji Nagai, A Harper, and Reena Salgia
The impact of tumor necrosis on tumor free survival in patients undergoing liver transplant with hepatocellular carcinoma: an analysis using the UNOS liver recipient explant pathology form., D Moonka, Reena Salgia, and A M. Harper
An argument for expanding the simultaneous liver and kidney transplant criteria: Validity of the new UNOS allocation policy., Shunji Nagai, M Safwan, Kelly Collins, Michael Rizzari, D Moonka, Kimberly A. Brown, Anita Patel, Atsushi Yoshida, and Marwan S. Abouljoud
Rapid deterioration of pre-transplant kidney function requiring dialysis is a prognostic factor in liver transplant alone, Shunji Nagai, Mohamed Safwan, Kelly Collins, Michael Rizzari, Dilip Moonka, Anita Patel, Kimberly A. Brown, Atsushi Yoshida, and Marwan Abouljoud
Course of inflammatory bowel disease activity in primary sclerosing cholangitis patients undergoing liver transplantation., R Parekh, M Segovia, and Nirmal Kaur
Successful management of patients with co-existent autoimmune hepatitis and graves' disease., S Rana, Arti Bhan, and Reena Salgia
Outcome of liver transplantation in patients with prior bariatric surgery., M Safwan, Marwan S. Abouljoud, and Reena Salgia
Statins in liver transplant recipients: Rates of use, mortality and rejection., Ranya Selim, Ahmed Abdulhamid, A Shyamraj, Andrew Watson, Jeffrey Tang, and Syed-Mohammed Jafri
Outcomes of TIPS for ascites as a function of baseline renal function., Ranya Selim, Todd Getzen, and Dilip Moonka
Lactate level immediate post-liver transplantation is a predictor of early allograft dysfunction., K Takahashi, Shunji Nagai, M Safwan, K Putchakayala, Kelly Collins, Michael Rizzari, Atsushi Yoshida, and Marwan S. Abouljoud
No impact of resistance-associated substitutions on the high efficacy of sofosbuvir-velpatasvir-voxilaprevir for 12 weeks in direct-acting antiviral-experienced patients: An integrated resistance analysis of the POLARIS-1 and POLARIS-4 studies, A C. Thompson, C Sarrazin, C L. Cooper, M P. Manns, R K. Reddy, K Kowdley, H Dvory-Sobol, E Svarovskia, R Martin, B P. Doehle, G Camus, L M. Stamm, R H. Hyland, D M. Brainard, H Mo, Stuart C. Gordon, M Bourliere, S Zeuzem, and S L. Flamm
Cold snare polypectomy is a safe and effective technique to remove large, partially circumferenctial duodenal polyps., R Vance and Cyrus Piraka
Real world effectiveness of 8 vs 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) in blacks with HCV: A comparative analysis of clinical trials with real world cohorts., E Wilson, P Davitkov, P Y. Kwo, S Kattakuzhy, K Qureshi, V Sundaram, S Naik, L A. Williams, J Wolf, J Llewellyn, A O. Osinusi, D M. Brainard, Stuart C. Gordon, L I. Backus, and K V. Kowdley
